MX2019010717A - Derivados de indol como inhibidores de bomba de eflujo. - Google Patents

Derivados de indol como inhibidores de bomba de eflujo.

Info

Publication number
MX2019010717A
MX2019010717A MX2019010717A MX2019010717A MX2019010717A MX 2019010717 A MX2019010717 A MX 2019010717A MX 2019010717 A MX2019010717 A MX 2019010717A MX 2019010717 A MX2019010717 A MX 2019010717A MX 2019010717 A MX2019010717 A MX 2019010717A
Authority
MX
Mexico
Prior art keywords
indole derivatives
pump inhibitors
efflux pump
compounds
formula
Prior art date
Application number
MX2019010717A
Other languages
English (en)
Inventor
J Lavoie Edmond
K Parhi Ajit
Yuan Yi
Zhang Yongzheng
Sun Yangsheng
Original Assignee
Univ Rutgers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rutgers filed Critical Univ Rutgers
Publication of MX2019010717A publication Critical patent/MX2019010717A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se describen compuestos de fórmula I: (ver fórmula I) y sales de estos. También se describen composiciones que comprenden compuestos de la fórmula I y compuestos de la fórmula I para usar en el tratamiento o prevención de infecciones bacterianas.
MX2019010717A 2017-03-10 2018-03-09 Derivados de indol como inhibidores de bomba de eflujo. MX2019010717A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762469987P 2017-03-10 2017-03-10
US201762523154P 2017-06-21 2017-06-21
PCT/US2018/021848 WO2018165611A1 (en) 2017-03-10 2018-03-09 Indole derivatives as efflux pump inhibitors

Publications (1)

Publication Number Publication Date
MX2019010717A true MX2019010717A (es) 2019-12-05

Family

ID=62044950

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010717A MX2019010717A (es) 2017-03-10 2018-03-09 Derivados de indol como inhibidores de bomba de eflujo.

Country Status (12)

Country Link
US (1) US20210094912A1 (es)
EP (1) EP3592736A1 (es)
JP (1) JP7323179B2 (es)
KR (1) KR20190138790A (es)
CN (1) CN110770224B (es)
AU (1) AU2018231120B2 (es)
BR (1) BR112019018691A2 (es)
CA (1) CA3061238A1 (es)
IL (1) IL269210A (es)
MX (1) MX2019010717A (es)
SG (1) SG11201908351TA (es)
WO (1) WO2018165611A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10556854B2 (en) 2016-02-24 2020-02-11 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
WO2017147335A1 (en) 2016-02-24 2017-08-31 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
US11180459B2 (en) 2017-03-10 2021-11-23 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
US11938114B2 (en) 2017-03-10 2024-03-26 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
WO2018218192A1 (en) * 2017-05-26 2018-11-29 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
US11458121B2 (en) 2017-06-26 2022-10-04 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection
US11845742B2 (en) 2017-11-14 2023-12-19 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection
KR20210053024A (ko) 2019-11-01 2021-05-11 에스엘 주식회사 차량용 램프

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238215A (en) * 1963-10-17 1966-03-01 Sterling Drug Inc 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines
US3465080A (en) * 1968-10-07 1969-09-02 American Cyanamid Co Therapeutic compositions containing morpholinoalkylene - indoles and methods of administering such in the treatment of depression
US4910193A (en) * 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5864039A (en) * 1994-03-30 1999-01-26 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compounds and use thereof as medicaments
US6506339B1 (en) * 1997-02-10 2003-01-14 Biomedical Design, Inc. Method of sterilization
ATE332130T1 (de) 1999-10-08 2006-07-15 Affinium Pharm Inc Fab-i-hemmer
US6730684B1 (en) * 1999-10-08 2004-05-04 Affinium Pharmaceuticals, Inc. Fab I inhibitors
US7365205B2 (en) * 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
HUP0103986A2 (hu) * 2001-09-28 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
GB0403038D0 (en) * 2004-02-11 2004-03-17 Novartis Ag Organic compounds
WO2007115231A2 (en) * 2006-03-30 2007-10-11 Chemocentryx, Inc. Cxcr4 modulators
FR2904317A1 (fr) * 2006-07-27 2008-02-01 Inst Nat Sante Rech Med Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques
AR070398A1 (es) * 2008-02-22 2010-03-31 Gruenenthal Chemie Derivados sustituidos de indol
EP2394653A1 (en) * 2010-05-26 2011-12-14 Almirall, S.A. Topical pharmaceutical compositions comprising mometasone furoate
FR2969150B1 (fr) 2010-12-20 2013-07-26 Centre Nat Rech Scient Nouvelles molecules indoliques demontrant des activites antibacteriennes dans une variete de bacteries a gram-negatif et positif dont des bacteries multidrogues-resistantes
EP2922843A4 (en) 2012-11-13 2016-06-01 Sloan Kettering Inst Cancer INDOLE COMPOUNDS AND THEIR USE AS ANTIMICROBIALS
US20170044100A1 (en) * 2014-04-22 2017-02-16 The Johns Hopkins University Inhibitors of drug-resistant mycobacterium tuberculosis
KR102496364B1 (ko) * 2014-09-10 2023-02-06 에피자임, 인코포레이티드 Ｓｍｙｄ 억제제
EP3331530A4 (en) 2015-08-03 2018-12-19 Raze Therapeutics Inc. Mthfd2 inhibitors and uses thereof
US11458121B2 (en) * 2017-06-26 2022-10-04 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection

Also Published As

Publication number Publication date
JP2020510044A (ja) 2020-04-02
AU2018231120B2 (en) 2022-06-23
SG11201908351TA (en) 2019-10-30
JP7323179B2 (ja) 2023-08-08
CA3061238A1 (en) 2018-09-13
CN110770224B (zh) 2022-11-18
AU2018231120A1 (en) 2019-10-31
KR20190138790A (ko) 2019-12-16
IL269210A (en) 2019-11-28
EP3592736A1 (en) 2020-01-15
CN110770224A (zh) 2020-02-07
WO2018165611A1 (en) 2018-09-13
US20210094912A1 (en) 2021-04-01
BR112019018691A2 (pt) 2020-04-07

Similar Documents

Publication Publication Date Title
MX2019010717A (es) Derivados de indol como inhibidores de bomba de eflujo.
PH12019501443A1 (en) Benzooxazole derivatives as immunomodulators
CR20200518A (es) Piridozinonas como inhibidores de parp7
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
MX2020009887A (es) Derivados de aminopiridina como inhibidores de ctps1.
MX2017012545A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
NZ733174A (en) Quinazoline derivatives used to treat hiv
MX2015017486A (es) Inhibidores de indolamina 2,3-dioxigenasa (dio).
EA201790779A1 (ru) Замещенные аминопуриновые соединения, их композиции и способы лечения с использованием таких соединений
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
CR20210265A (es) Derivados de aminopirimidina/pirazina como inhibidores de ctps1
PH12017501019A1 (en) Isoxazole hydromaxamic acid compounds as lpxc inhibitors
EA201791451A1 (ru) 5-[(пиперазин-1-ил)-3-оксо-пропил]-имидазолидин-2,4-дионовые производные в качестве ингибиторов adamts для лечения остеоартрита
PH12021550382A1 (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
EA201992320A1 (ru) Пиперидины в качестве ковалентных ингибиторов менина
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
AU2017269673A1 (en) Pyridine dicarboxamide derivatives as bromodomain inhibitors
EA201991253A1 (ru) Бензодиазолиевые соединения в качестве ингибиторов enac
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
MX2015010619A (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer.
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
MX2018014813A (es) Composiciones antibacterianas.